Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial
Author:
Shrestha AlvinORCID, Bashir Tufail, Achison Marcus, Adamson Simon, Akpan Asangaedem, Aspray Terry, Avenell Alison, Band Margaret M., Burton Louise A., Cvoro Vera, Donnan Peter T., Duncan Gordon W., George Jacob, Gordon Adam L., Gregson Celia L., Hapca Adrian, Hume Cheryl, Jackson Thomas A., Kerr Simon, Kilgour Alixe, Masud Tahir, McKenzie Andrew, McKenzie Emma, Patel HarnishORCID, Pilvinyte KristinaORCID, Roberts Helen C., Sayer Avan A., Rossios Christos, Smith Karen T., Soiza Roy L.ORCID, Steves Claire J., Struthers Allan D., Tiwari Divya, Whitney Julie, Witham Miles D., Kemp Paul R.
Abstract
Introduction
Understanding genetic contributors to sarcopenia (age-related loss of muscle strength and mass) is key to finding effective therapies. Variants of the bradykinin receptor 2 (BDKRB2) have been linked to athletic and muscle performance. The rs1799722–9 and rs5810761 T alleles have been shown to be overrepresented in endurance athletes, possibly due to increased transcriptional rates of the receptor. These variants have been rarely studied in older people or people with sarcopenia.
Methods
We performed a post hoc sub-study of the Leucine and ACE (LACE) inhibitor trial, which enrolled 145 participants aged ≥70 years with low grip strength and low gait speed. Participants’ blood samples were genotyped for rs179972 using TaqMan and rs5810761 by amplification through Hotstar Taq. Genotypes were compared with outcomes of physical performance and body composition measures.
Results
Data from 136 individuals were included in the analysis. For rs1799722 the genotype frequency (TT: 17, CC: 48, CT: 71) remained in Hardy-Weinberg Equilibrium (HWE p = 0.248). There was no difference between the genotypes for six-Minute Walk Distance (6MWD) or Short Physical Performance Battery (SPPB). Men with the TT genotype had a significantly greater 6MWD than other genotypes (TT 400m vs CT 310m vs CC 314m, p = 0.027), and greater leg muscle mass (TT 17.59kg vs CT 15.04kg vs CC 15.65kg, p = 0.007). For rs5810761, the genotype frequency (-9-9: 31, +9+9: 43, -9+9: 60) remained in HWE (p = 0.269). The +9+9 genotype was associated with a significant change in SPPB score at 12 months (-9-9 0 vs -9+9 0 vs +9+9–1, p<0.001), suggesting an improvement. In men, the -9-9 genotype was associated with lower arm fat (-9-9 2.39kg vs -9+9 2.72kg vs +9+9 2.76kg, p = 0.019).
Conclusion
In men, the rs1799722 TT genotype was associated with longer 6MWD and greater leg muscle mass, while the rs5810761 -9-9 genotype was associated with lower arm fat mass.
Funder
Efficacy and Mechanism Evaluation (EME) Programme NIHR Newcastle Biomedical Research Centre Health Services Research Unit
Publisher
Public Library of Science (PLoS)
Reference31 articles.
1. Sarcopenia.;AJ Cruz-Jentoft;The Lancet,2019 2. Muscle wasting in the presence of disease, why is it so variable?;PR Kemp;Biol Rev,2019 3. The Renin-Angiotensin System and Skeletal Muscle.;SK Powers;Exerc Sport Sci Rev.,2018 4. Angiotensin II Induces Skeletal Muscle Wasting through Enhanced Protein Degradation and Down-Regulates Autocrine Insulin-Like Growth Factor I.;M Brink,2001 5. Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1;P Du Bois;Expression. Circ Res,2015
|
|